Diabetic Macular Edema: Options for Adjunct Therapy.

Area of Science:

• Ophthalmology
• Endocrinology
• Vascular Biology

Background:

• Diabetes mellitus (DM) affects 387 million globally, with diabetic retinopathy (DR) a leading cause of blindness.
• Diabetic macular edema (DME), a complication of DR, involves retinal vascular hyperpermeability and exudates, threatening central vision.
• Timely intervention for DR can prevent severe vision loss in over 90% of cases.

Purpose of the Study:

• To review the advancements in treating diabetic macular edema (DME).
• To highlight the efficacy of anti-VEGF agents and intravitreal steroids in managing DME.
• To establish the current standard of care for center-involved DME.

Main Methods:

• Review of pivotal randomized, prospective, multicenter clinical trials (e.g., RESOLVE, RISE/RIDE, VISTA/VIVID, DRCR.net protocol T).
• Analysis of data from studies evaluating intravitreal ranibizumab, aflibercept, bevacizumab, dexamethasone, and fluocinolone acetonide.
• Assessment of outcomes including best-corrected visual acuity and central retinal thickness via optical coherence tomography.

Main Results:

• Anti-vascular endothelial growth factor (anti-VEGF) agents like ranibizumab, aflibercept, and bevacizumab have shown significant improvements in visual acuity and reduced retinal thickness.
• Intravitreal steroids are effective, particularly for refractory DME cases.
• Blocking VEGF and inflammation has revolutionized DME treatment, improving visual outcomes.

Conclusions:

• Anti-VEGF therapy and intravitreal steroids represent a new standard of care for center-involved DME.
• These therapies have dramatically improved visual outcomes and reduced the risk of severe vision loss in DME patients.
• Continued research and application of these treatments are crucial for managing diabetic eye disease.